BioAtla (BCAB) Net Cash Flow (2020 - 2026)
BioAtla (BCAB) posted quarterly Net Cash Flow of -$5.2 million for Q1 2026, up 69.09% year-over-year from -$3.0 million in Q1 2025, and down 329.03% quarter-over-quarter from -$1.2 million in Q4 2025.
BioAtla (BCAB) Net Cash Flow (2020 - 2026) Analysis & Trends
BioAtla's Net Cash Flow history runs 7 years deep, the most recent figure standing at -$5.2 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 69.09% year-over-year to -$5.2 million; the TTM figure through Mar 2026 stood at -$30.4 million (up 37.01% YoY), while the FY2025 annual figure was -$41.9 million, up 32.83% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$5.2 million, down from -$1.2 million in the prior quarter.
- The five-year high for Net Cash Flow was $37.4 million in Q4 2022, with the low at -$30.8 million in Q1 2024.
- The 5-year median for Net Cash Flow is -$17.1 million (2022), against an average of -$14.3 million.
- The sharpest annual moves came in 2022 and 2023: Net Cash Flow surged 249.87% in 2022, then sank 179.74% in 2023.
- BioAtla's Net Cash Flow stood at $37.4 million in 2022, then tumbled by 179.74% to -$29.8 million in 2023, then soared by 74.94% to -$7.5 million in 2024, then surged by 83.91% to -$1.2 million in 2025, then sank by 329.03% to -$5.2 million in 2026.
- Business Quant data shows BCAB's Net Cash Flow at -$5.2 million in Q1 2026, -$1.2 million in Q4 2025, and -$9.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | BioAtla | 5.28 Mn | 5.28 Mn | - | -417,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -417,000.00 |
| Jun 30, 2026 | -417,000.00 |
| Mar 31, 2026 | -5.16 Mn |
| Mar 31, 2026 | -5.16 Mn |
| Dec 31, 2025 | -1.20 Mn |
| Dec 31, 2025 | -1.20 Mn |
| Sep 30, 2025 | -9.89 Mn |
| Sep 30, 2025 | -9.89 Mn |
| Jun 30, 2025 | -14.16 Mn |
| Jun 30, 2025 | -14.16 Mn |
| Mar 31, 2025 | -16.68 Mn |
| Mar 31, 2025 | -16.68 Mn |
| Dec 31, 2024 | -7.47 Mn |
| Dec 31, 2024 | -7.47 Mn |
| Sep 30, 2024 | -5.15 Mn |
| Sep 30, 2024 | -5.15 Mn |
| Jun 30, 2024 | -18.97 Mn |
| Jun 30, 2024 | -18.97 Mn |
| Mar 31, 2024 | -30.84 Mn |
| Mar 31, 2024 | -30.84 Mn |